Lenolidomide is an immunotherapy medicine used in treatment of CLL, SLL and Mantle Cell Lymphoma with a promising
outlook in treatment of other subtypes of lymphoma in the future. Lenolidomide works by activating the body’s immune
system to target and kill the lymphoma cells and helps prevent the lymphoma cells from growing by cutting off their
blood supply that they require to exist.
Lenalidomide is an oral tablet that you take every day.
Lenalidomide may have the following side effects;
Lowered blood counts
Swelling of the limbs and skin
Lenolidomide is approved by the TGA for the following indications;
Mantle Cell Lymphoma as a second line treatment
Other types of lymphoma are currently being reviewed for listing on the PBS and access to lenalidomide can also
be found in clinical trials in Australia and by access programs through the pharmaceutical company.